• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates

    5/1/24 2:32:12 PM ET
    $CETX
    $CTMX
    $CVRX
    $LEG
    Electrical Products
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CETX alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 200 points on Wednesday. The Federal Reserve opted to keep the federal funds rate unchanged at 5.25% to 5.5%, as widely expected.

    The Dow traded up 0.55% to 38,022.21 while the NASDAQ rose 0.19% to 15,687.08. The S&P 500 also rose, gaining, 0.08% to 5,039.51.

    Check This Out: This Analyst With 86% Accuracy Rate Sees More Than 24% Upside In Lattice Semiconductor – Here Are 5 Stock Picks For April From Wall Street’s Most Accurate Analysts

    Leading and Lagging Sectors

    Utilities shares rose by 1.2% on Wednesday.

    In trading on Wednesday, energy shares fell by 1.6%.

    Top Headline

    Pfizer Inc. (NYSE:PFE) reported better-than-expected first-quarter financial results.

    Pfizer reported first-quarter adjusted EPS of 82 cents, down 33% year over year, beating the consensus of 54 cents. The U.S. drugmaker reported sales of $14.9 billion, down 20%, beating the consensus of $14.2 billion.

    The company expects adjusted EPS of $2.15-$2.35 in 2024 compared with a prior forecast of $2.05 to $2.25 and the consensus of $2.76.

    Equities Trading UP
                           

    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares shot up 148% to $4.04. The company said it will report first-quarter results and provide an initial CX-904 Phase 1a dose escalation update on May 8 after the close of markets.
    • Shares of TransMedics Group, Inc. (NASDAQ:TMDX) got a boost, surging 27% to $119.15 after the company raised its 2024 guidance.
    • Rocky Brands, Inc. (NASDAQ:RCKY) shares were also up, gaining 24% to $32.06 after the company reported better-than-expected quarterly financial results.

    Equities Trading DOWN

    • Cemtrex, Inc. (NASDAQ:CETX) shares dropped 72% to $0.3164 after the company announced pricing of a $10 million upsized underwritten public offering.
    • Shares of CVRx, Inc. (NASDAQ:CVRX) were down 35% to $10.02 after the company reported worse-than-expected first-quarter financial results. JP Morgan analyst Robbie Marcus downgraded the stock from Overweight to Neutral and lowered the price target from $36 to $13.
    • Leggett & Platt, Incorporated (NYSE:LEG) was down, falling 27% to $13.12 after the company reported worse-than-expected first-quarter financial results. The company also reduced its dividend.

    Also Check This Out: Exxon Mobil, Kimberly-Clark And 2 Other Stocks Insiders Are Selling

    Commodities

    In commodity news, oil traded down 3.3% to $79.23 while gold traded up 0.5% at $2,315.00.

    Silver traded up 0.4% to $26.755 on Wednesday, while copper fell 0.4% to $4.5470.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 slipped 0.11%, while London's FTSE 100 fell 0.28%.

    The S&P Global UK manufacturing PMI was revised higher to 49.1 in April from a preliminary reading of 48.7, while Nationwide House Price Index increased 0.6% year-over-year in April.

    Asia Pacific Markets

    Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 falling 0.34%.

    Japan's au Jibun Bank manufacturing PMI was revised lower to 49.6 in April compared to preliminary reading of 49.9.

    Economics

    • U.S. mortgage applications declined by 2.3% from the prior week in the period ending April 26.
    • U.S. private employers added 192,000 new jobs during the month of April, compared to a revised 208,000 in March, topping market estimates of a 175,000 gain.
    • The S&P Global manufacturing PMI declined to 50 in April versus 51.9 a month ago.
    • U.S. construction spending declined by 0.2% from the prior month in March.
    • The number of job openings fell by 325,000 from the prior month to 8.488 million in March.
    • The ISM manufacturing PMI declined to 49.2 in April from 50.3 a month ago.
    • U.S. crude oil inventories rose by 7.265 million barrels in the week ending April 26, compared to a 6.368 million barrel fall in the prior week.

    Now Read This: Amazon To Rally Over 37%? Here Are 10 Top Analyst Forecasts For Wednesday

    Get the next $CETX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CETX
    $CTMX
    $CVRX
    $LEG

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Pfizer Inc.
    $PFE
    12/2/2025$26.00Neutral
    Citigroup
    Pfizer Inc.
    $PFE
    11/13/2025$30.00Sector Outperform
    Scotiabank
    TransMedics Group Inc.
    $TMDX
    10/23/2025$148.00Hold → Buy
    Needham
    TransMedics Group Inc.
    $TMDX
    10/13/2025$145.00Buy
    Jefferies
    CytomX Therapeutics Inc.
    $CTMX
    9/22/2025$6.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CETX
    $CTMX
    $CVRX
    $LEG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pfizer downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00

    2/12/26 7:23:25 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Pfizer with a new price target

    UBS resumed coverage of Pfizer with a rating of Neutral and set a new price target of $25.00

    1/7/26 9:13:33 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    SEC Filings

    View All

    Leggett & Platt Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - LEGGETT & PLATT INC (0000058492) (Filer)

    2/11/26 4:34:51 PM ET
    $LEG
    Home Furnishings
    Consumer Discretionary

    Cemtrex Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

    8-K - CEMTREX INC (0001435064) (Filer)

    2/11/26 8:04:02 AM ET
    $CETX
    Electrical Products
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    2/5/26 1:20:38 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Hassanein Waleed H bought $1,000,350 worth of shares (8,775 units at $114.00) (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    11/18/25 4:30:07 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Smith Dwight Eric bought $8,694 worth of shares (300 units at $28.98), increasing direct ownership by 2% to 14,207 units (SEC Form 4)

    4 - ROCKY BRANDS, INC. (0000895456) (Issuer)

    11/7/25 4:20:17 PM ET
    $RCKY
    Shoe Manufacturing
    Consumer Discretionary

    President & CEO Hassanein Waleed H bought $1,982,121 worth of shares (16,875 units at $117.46) (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    8/8/25 4:30:13 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Leggett & Platt Reports 4Q and Full Year 2025 Results

    CARTHAGE, Mo., Feb. 11, 2026 /PRNewswire/ -- 4Q sales of $939 million, an 11% decrease vs 4Q244Q EPS of $.18, 4Q adjusted1 EPS of $.22, a $.01 increase vs adjusted1 4Q24 EPS2025 sales of $4.05 billion, a 7% decrease vs 20242025 EPS of $1.69, 2025 adjusted1 EPS of $1.05, flat vs adjusted1 2024 EPS2025 operating cash flow of $338 million, a $33 million increase vs 20242026 guidance: sales of $3.8–$4.0 billion, EPS of $0.92–$1.38; adjusted1 EPS of $1.00–$1.20President and CEO Karl Glassman commented, "Throughout 2025, our teams executed our strategic priorities, including strengthening our balance sheet, improving operational efficiency, and positioning the company for long-term growth. We made

    2/11/26 4:10:00 PM ET
    $LEG
    Home Furnishings
    Consumer Discretionary

    PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

    The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others, along with increasing applicability in neurodegenerative and inflammatory diseases, are further fueling sustained R&D investment. LAS VEGAS, Feb. 10, 2026 /PRNewswire/ -- DelveInsight's PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment prac

    2/10/26 5:31:00 PM ET
    $ARVN
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Pres. - Spec. and FF&T Smith Robert S Jr was granted 243 shares, increasing direct ownership by 0.23% to 107,856 units (SEC Form 4)

    4 - LEGGETT & PLATT INC (0000058492) (Issuer)

    2/9/26 2:50:21 PM ET
    $LEG
    Home Furnishings
    Consumer Discretionary

    EVP - Chief HR Officer Odaffer Lindsey Nicole was granted 62 shares, increasing direct ownership by 0.10% to 64,125 units (SEC Form 4)

    4 - LEGGETT & PLATT INC (0000058492) (Issuer)

    2/9/26 2:47:35 PM ET
    $LEG
    Home Furnishings
    Consumer Discretionary

    EVP-Chief Strategic Plan. Off. Kleiboeker Ryan Michael was granted 67 shares, increasing direct ownership by 0.08% to 88,535 units (SEC Form 4)

    4 - LEGGETT & PLATT INC (0000058492) (Issuer)

    2/9/26 2:45:03 PM ET
    $LEG
    Home Furnishings
    Consumer Discretionary

    $CETX
    $CTMX
    $CVRX
    $LEG
    Financials

    Live finance-specific insights

    View All

    Leggett & Platt Reports 4Q and Full Year 2025 Results

    CARTHAGE, Mo., Feb. 11, 2026 /PRNewswire/ -- 4Q sales of $939 million, an 11% decrease vs 4Q244Q EPS of $.18, 4Q adjusted1 EPS of $.22, a $.01 increase vs adjusted1 4Q24 EPS2025 sales of $4.05 billion, a 7% decrease vs 20242025 EPS of $1.69, 2025 adjusted1 EPS of $1.05, flat vs adjusted1 2024 EPS2025 operating cash flow of $338 million, a $33 million increase vs 20242026 guidance: sales of $3.8–$4.0 billion, EPS of $0.92–$1.38; adjusted1 EPS of $1.00–$1.20President and CEO Karl Glassman commented, "Throughout 2025, our teams executed our strategic priorities, including strengthening our balance sheet, improving operational efficiency, and positioning the company for long-term growth. We made

    2/11/26 4:10:00 PM ET
    $LEG
    Home Furnishings
    Consumer Discretionary

    TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (800) 7

    2/10/26 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cemtrex Completes Acquisition of Richland Industries, Expanding Its Industrial Services Platform into the Southeast

    Hauppauge, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- – Cemtrex, Inc. (NASDAQ:CETX) today announced that its Advanced Industrial Services ("AIS") subsidiary has acquired all the assets of Richland Industries ("Richland"), an industrial services and fabrication company located in Tennessee. In connection with the transaction, AIS established a new subsidiary, AIS Tennessee to acquire and operate the business and its primary facility. The acquisition extends the Company's industrial services platform into one of the fastest-growing industrial regions in the United States.  The transaction represents a significant next step in AIS's multi-year evolution. Since fiscal 2022, AIS has grown from app

    2/5/26 4:10:00 PM ET
    $CETX
    Electrical Products
    Technology

    $CETX
    $CTMX
    $CVRX
    $LEG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cemtrex Inc.

    SC 13G - CEMTREX INC (0001435064) (Subject)

    11/14/24 5:51:51 PM ET
    $CETX
    Electrical Products
    Technology

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:00:06 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company's strategy and business development functions.   "Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers," said Sean McCarthy, D.Phil., president, chief executive offic

    10/20/25 4:05:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care